Celularity (CELU) Operating Expenses (2019 - 2025)
Celularity (CELU) posted quarterly Operating Expenses of $26.2 million for Q4 2025, down 4.56% year-over-year from $27.4 million in Q4 2024, and up 43.87% quarter-over-quarter from $18.2 million in Q3 2025.
Celularity (CELU) Operating Expenses (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Operating Expenses for 7 consecutive years, with $26.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses fell 4.56% year-over-year to $26.2 million; the TTM figure through Dec 2025 stood at $87.9 million (down 5.1% YoY), while the FY2025 annual figure was $87.9 million, down 5.1% from the prior year.
- Operating Expenses climbed to $26.2 million in Q4 2025 per CELU's latest filing, from $18.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $103.0 million in Q3 2023 and bottomed at -$13.4 million in Q4 2022.
- Historically, Operating Expenses has averaged $28.5 million across 5 years, with a median of $22.0 million in 2024.
- Annual changes were most pronounced in 2021 — Operating Expenses surged 30542.6% — and 2022, when it slumped 167.43%.
- Celularity's Operating Expenses stood at $19.8 million in 2021, then plunged by 167.43% to -$13.4 million in 2022, then soared by 90.99% to -$1.2 million in 2023, then jumped by 2378.64% to $27.4 million in 2024, then retreated by 4.56% to $26.2 million in 2025.
- Business Quant data shows CELU's Operating Expenses at $26.2 million in Q4 2025, $18.2 million in Q3 2025, and $21.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | 26.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 26.16 Mn |
| Sep 30, 2025 | 18.18 Mn |
| Jun 30, 2025 | 21.60 Mn |
| Mar 31, 2025 | 21.91 Mn |
| Dec 31, 2024 | 27.41 Mn |
| Sep 30, 2024 | 20.82 Mn |
| Jun 30, 2024 | 22.29 Mn |
| Mar 31, 2024 | 22.06 Mn |
| Dec 31, 2023 | -1.20 Mn |
| Sep 30, 2023 | 103.04 Mn |
| Jun 30, 2023 | 45.41 Mn |
| Mar 31, 2023 | 67.81 Mn |
| Dec 31, 2022 | -13.36 Mn |
| Sep 30, 2022 | 9.78 Mn |
| Jun 30, 2022 | -399,000.00 |
| Mar 31, 2022 | 47.55 Mn |
| Dec 31, 2021 | 19.81 Mn |
| Sep 30, 2021 | -276,000.00 |
| Jun 30, 2021 | 63.81 Mn |
| Mar 31, 2021 | 47.06 Mn |